Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2008 1
2009 1
2010 3
2011 1
2012 5
2013 3
2014 6
2015 4
2016 6
2017 5
2018 7
2019 7
2020 9
2021 3
2022 14
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy.
Bonazzi S, d'Hennezel E, Beckwith REJ, Xu L, Fazal A, Magracheva A, Ramesh R, Cernijenko A, Antonakos B, Bhang HC, Caro RG, Cobb JS, Ornelas E, Ma X, Wartchow CA, Clifton MC, Forseth RR, Fortnam BH, Lu H, Csibi A, Tullai J, Carbonneau S, Thomsen NM, Larrow J, Chie-Leon B, Hainzl D, Gu Y, Lu D, Meyer MJ, Alexander D, Kinyamu-Akunda J, Sabatos-Peyton CA, Dales NA, Zécri FJ, Jain RK, Shulok J, Wang YK, Briner K, Porter JA, Tallarico JA, Engelman JA, Dranoff G, Bradner JE, Visser M, Solomon JM. Bonazzi S, et al. Among authors: lu h. Cell Chem Biol. 2023 Mar 16;30(3):235-247.e12. doi: 10.1016/j.chembiol.2023.02.005. Epub 2023 Mar 1. Cell Chem Biol. 2023. PMID: 36863346 Free article.
Chinese scientists and US leadership in the life sciences.
Holtzman SH, Cohen R, Levin JM, Maraganore J; Signatories to the Statement. Holtzman SH, et al. Nat Biotechnol. 2019 Nov;37(11):1261-1263. doi: 10.1038/s41587-019-0285-x. Nat Biotechnol. 2019. PMID: 31582856 No abstract available.
Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.
Schwartz S, Patel N, Longmire T, Jayaraman P, Jiang X, Lu H, Baker L, Velez J, Ramesh R, Wavreille AS, Verneret M, Fan H, Hu T, Xu F, Taraszka J, Pelletier M, Miyashiro J, Rinne M, Dranoff G, Sabatos-Peyton C, Cremasco V. Schwartz S, et al. Among authors: lu h. Immunother Adv. 2022 Aug 10;2(1):ltac019. doi: 10.1093/immadv/ltac019. eCollection 2022. Immunother Adv. 2022. PMID: 36196369 Free PMC article.
78 results